Details of the Drug Pharmacogenomic Perturbation Atlas

Resiquimod Drug Info

Resiquimod [INN]; R 848; S 28463; R-848; S-28463; VML-600; 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol; 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 4-amino-2-(ethoxymethyl)-a,a-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol; 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol

Cross-matching ID

PubChem CID

159603

ChEBI ID

CHEMBL383322

CAS Number

CAS 144875-48-9

TTD Drug ID

D0C8KF

General Information of Drug (ID: DML6XSP)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	1.96	1.37e-2	34/36 (94.44%)	PCNA;RPA3;POLE3;...
Allograft rejection	1.85	3.44e-2	32/38 (84.21%)	HLA-DRA;CD40;HLA-DPA1;...
Proteasome	1.84	2.29e-2	44/46 (95.65%)	PSMB9;PSMB3;PSMA4;...
Th1 and Th2 cell differentiation	1.82	2.06e-2	80/92 (86.96%)	HLA-DRA;HLA-DPA1;HLA-DRB1;...
Asthma	1.81	2.75e-2	25/31 (80.65%)	HLA-DRA;CD40;HLA-DPA1;...
TGF-beta signaling pathway	1.80	2.52e-2	81/94 (86.17%)	ID1;ID3;BMP4;...
Systemic lupus erythematosus	1.79	3.73e-2	45/135 (33.33%)	HLA-DRA;CD40;ACTN1;...
TNF signaling pathway	1.75	4.81e-2	103/112 (91.96%)	CCL5;BIRC3;CXCL10;...
Epstein-Barr virus infection	1.75	4.43e-2	189/202 (93.56%)	HLA-DRA;CYCS;CD40;...
Type I diabetes mellitus	1.74	4.40e-2	38/43 (88.37%)	HLA-DRA;CPE;HLA-DPA1;...
Primary immunodeficiency	1.73	4.25e-2	33/38 (86.84%)	CD40;LCK;TAP1;...
Amino sugar and nucleotide sugar metabolism	1.73	4.01e-2	38/48 (79.17%)	UGP2;NAGK;UAP1;...
Intestinal immune network for IgA production	1.72	4.44e-2	38/48 (79.17%)	HLA-DRA;CD40;HLA-DPA1;...
Prion disease	1.71	4.42e-2	209/273 (76.56%)	CYCS;CCL5;CAV1;...
Bacterial invasion of epithelial cells	1.71	4.12e-2	59/77 (76.62%)	CAV1;PIK3CD;CDC42;...
Viral myocarditis	1.71	3.95e-2	53/60 (88.33%)	HLA-DRA;CYCS;CD40;...
Glycine, serine and threonine metabolism	-1.98	6.10e-3	31/40 (77.5%)	AGXT;GNMT;SHMT1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.04uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H